article · BMC Infectious Diseases
The emergence of resistance is of great concern in the control of TB, especially to the new and repurposed drugs needed for the treatment of rifampicin resistance. We report a patient from South Kivu in the Eastern Democratic Republic of the Congo with primary resistance to delamanid and linezolid without treatment experience with these drugs. The identification of novel resistance mutations raises concerns about the potential global spread and poor outcomes of the WHO-recommended oral treatment regimens, highlighting the need for the urgent rollout of DST.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1186/s12879-025-11348-w
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
